Haematology

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #Haematology #Oncology

Coalition aims to double CAR-T therapy access by 2030

CAR T Vision has launched to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR-T therapy.   By 2030, the coalition aims to double the proportion of eligible patients treated with CAR-T therapy.   As outlined in a… Read More

#News

Blood cancer
#Cell therapy #CHMP #European Commission #Haematology #Oncology #Stem cells

Stem cell therapy gets positive CHMP opinion for blood cancers

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting conditional marketing authorisation for Zemcelpro (UM171 cell therapy).  The positive opinion relates to the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem… Read More

#News #Regulatory

Blood cells
#Blood cancer #Clinical trials #EHA #Haematology #Oncology

Data highlights from EHA 2025

The latest new trial data presented at the 30th European Hematology Association (EHA) 2025 Congress.  Bispecific antibody for diffuse large B-cell lymphoma Genmab shared new results from the Phase Ib/II EPCORE NHL-2 trial Arm 10 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously,… Read More

#Cancer Research #News

#Combination therapy #Haematology #Lymphoma #Oncology #The Institute of Cancer Research

Drug combination treats B-cell lymphoma

Research published in the journal Blood shows that the drug tazemetostat could work better when combined with another targeted drug.   For patients with follicular lymphoma, treatment can include the drug tazemetostat – but patients have varying responses, and some see their cancer… Read More

#Cancer Research #Editor's Choice #News

Gastrointestinal tract
#Cancer research #Gastrointestinal #Gastrointestinal cancer #Haematology

In Conversation With: Dr Emil Lou, University of Minnesota

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr Emil Lou,… Read More

#News

Chinese flag
#Ascentage Pharma #Blood cancer #China #Haematology #Oncology

Ascentage celebrates inclusion in Chinese oncology guidelines

Two of Ascentage Pharma’s drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines.   Lisaftoclax (APG-2575), an investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies.  This makes… Read More

#News

CAR-T therapy
#CAR-T #Cell therapy #Haematology #Lymphoma #March Biosciences #Phase II trial

Phase II trial starts for CAR-T therapy in T-cell lymphoma

March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.   “This represents a significant milestone in advancing MB-105 as a potential treatment… Read More

#Cancer Research #News

Leukaemia
#Acute Myeloid Leukaemia #FDA #Haematology #Oncology #Pleco Therapeutics

Positive FDA outcome for PTX-252 in acute myeloid leukaemia

Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, has announced a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the US Food and Drug Administration (FDA).   The meeting addressed the continued development of PTX-252, an intravenous (IV) formulation designed to treat… Read More

#News #Regulatory

T cells attacking cancer
#Cell therapy #Haematology #Oncology #Orca Bio #Phase III trial

Allogeneic T-cell therapy doubles rate of survival free from GvHD

Biotechnology company Orca Bio has revealed positive results from the Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with haematological malignancies.  The trial included patients with acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute… Read More

#Cancer Research #News #Trending News

Cancer cell
#CAR-T #Cell therapy #Haematology #Interview #March Biosciences #Oncology

Pushing past the limitations of CAR-T therapies

DDW Editor Reece Armstrong speaks to Sarah Hein, CEO and Co-founder of March Biosciences, about the company’s recent fundraising efforts and its development of CAR-T therapies addressing challenging blood cancers. RA: What are the limitations of current standard-of-care therapies for blood cancers? SH: There are many treatment options for the… Read More

#Exclusive Content

Nasdaq stock market
#Ascentage Pharma #Haematology #Market reporting #Oncology

Hong Kong based Ascentage Pharma lists on Nasdaq

Ascentage Pharma has listed on the Nasdaq Global Market, becoming the first 18A company to achieve a dual listing on the US stock market.   Ascentage Pharma offered 7,325,000 American depositary shares (ADS) at $17.25 per ADS. The proceeds from the offering are expected to be approximately $126.4… Read More

#Business & Investment #News

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #FDA #Haematology #March Biosciences #Oncology

FDA Orphan Drug Designation for CD5 CAR-T cell therapy

The US Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, March Biosciences’ CD5-targeted CAR-T cell therapy for the treatment of relapsed/refractory CD5-positive T-cell lymphoma (TCL).  MB-105 is in development as a treatment for TCL, T-cell acute lymphoblastic leukaemia (T-ALL), chronic lymphocytic leukaemia (CLL),… Read More

#News #Regulatory

Blood cancer
#Blood cancer #Funding #Haematology #Leukaemia #Washington University School of Medicine

$10.8 million grant supports leukaemia drug discovery projects

Washington University School of Medicine in St Louis has been awarded a five-year $10.8 million grant to further its programmes in leukaemia and other blood cancers.  The grant, from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), renews funding for the Specialized Program… Read More

#Business & Investment #News

Stem cell transplant
#Graft vs Host Disease #Haematology #JAK inhibitor #Stem cells #Washington University School of Medicine

JAK inhibitor prevents GvHD in ‘half-matched’ stem cell transplants

Adding a new drug to standard care for stem cell transplant recipients may reduce graft-versus-host disease (GvHD), according to an early-stage clinical trial conducted at Washington University School of Medicine in St Louis.   The trial showed that patients being treated for various blood cancers tolerated the… Read More

#News #Trending News

Blood cancer
#Blood cancer #CAR-T #Cell therapy #Haematology #Oncology #Phase I trial #Synthekine

Positive initial results from trial of CD19 CAR-T in blood cancers

Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies.  In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of… Read More

#Cancer Research #News

CAR-T cell therapy
#CAR-T #Cell therapy #Financing #Fundraising #Haematology #March Biosciences #Oncology

March Bio raises $28.4m for autologous CAR-T therapy

Biotechnology company March Biosciences (March Bio) has announced the close of a $28.4 million oversubscribed Series A financing, having raised over $51 million to date. Mission BioCapital and 4BIO Capital led the financing, with participation from KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and… Read More

#Business & Investment #News